Picture of TriMas logo

TRS — TriMas News Story

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsBalancedMid CapSuper Stock

Industrial container firm TriMas beats Q2 sales estimates, raises FY 25 guidance

Overview

TriMas Q2 sales rise 14.2%, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 up 41.9%, surpassing analyst estimates, per LSEG data

Company raises full-year 2025 earnings outlook, citing strong segment performance

Outlook

TriMas raises 2025 EPS outlook to $1.95-$2.10 from $1.70-$1.85

Company expects 2025 sales growth of 8%-10%, up from 4%-6%

TriMas cites strong Aerospace performance for guidance increase

Company monitoring tariff impacts, focusing on performance improvements

Result Drivers

AEROSPACE SALES - Aerospace segment sales increased 32.5% due to higher industry build rates, new awards, and acquisition of TriMas Aerospace Germany

PACKAGING GROWTH - Packaging segment sales rose 8.4%, driven by organic growth in beauty & personal care and industrial markets

SPECIALTY PRODUCTS DECLINE - Specialty Products sales fell 6.8% due to the divestiture of Arrow Engine

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 SalesBeat$274.80 mln$251.20 mln (2 Analysts)
Q2 Adjusted EPSBeat$0.61$0.48 (2 Analysts)
Q2 EPS$0.41
Q2 Adjusted Net Income$25.10 mln
Q2 Adjusted Operating Income$31.80 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the non-paper containers & packaging peer group is "buy" Wall Street's median 12-month price target for TriMas Corp is $34.15, about 7.8% above its July 28 closing price of $31.48 The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago Press Release: ID:nBwbRSSNMa (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on TriMas

See all news